Goldman Sachs Group Inc vs Medtronic PLC — how do they compare? Goldman Sachs Group Inc trades at $1,036.76 (market cap $301.19B), while Medtronic PLC trades at $90.48 (market cap $116.07B). The key difference: Goldman Sachs Group Inc is far larger — about 2.6× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| GS | MDT | |
|---|---|---|
Market Cap | $301.19B | $116.07B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $105.35 |
52-Week Low | $715.95 | $73.75 |
Dividend Yield | 1.93% | 3.18% |
Enterprise Value | — | $134.82B |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.
The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →